Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 5/2018

01-10-2018

Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis

Authors: Melissa Sum, Franco Vallejo Garcia

Published in: Pituitary | Issue 5/2018

Login to get access

Excerpt

Combination therapy with nivolumab, an anti-programmed cell death-1 antibody, and ipilimumab, an anti-cytotoxic T-lymphocyte-associated antigen4 compared to ipilimumab alone leads to significantly longer overall survival in patients with advanced melanoma [1]. …
Literature
1.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356CrossRefPubMedPubMedCentral
2.
Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19:82–92CrossRefPubMed
3.
Marchand L, Paulus V, Fabien N, Perol M, Thivolet C, Vouillarmet J, Saintigny P (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol 12(11):e182–e184CrossRef
Metadata
Title
Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis
Authors
Melissa Sum
Franco Vallejo Garcia
Publication date
01-10-2018
Publisher
Springer US
Published in
Pituitary / Issue 5/2018
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-018-0880-8

Other articles of this Issue 5/2018

Pituitary 5/2018 Go to the issue

OriginalPaper

Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study

ReviewPaper

Two types of ectopic Cushing syndrome or a continuum? Review

OriginalPaper

Optical coherence tomography retinal ganglion cell complex analysis for the detection of early chiasmal compression

OriginalPaper

Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome

OriginalPaper

Twelve cases of pituitary metastasis: a case series and review of the literature

OriginalPaper

An early post-operative ACTH suppression test can safely predict short- and long-term remission after surgery of Cushing’s disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits